Clinical trials: Glomerulosclerosis
Focal Segmental Glomerulosclerosis
Safety and Pharmacokinetics of FG-3019 in Adolescents and Adults With Focal Segmental Glomerulosclerosis (FSGS)
The purpose of this study is to evaluate the safety and tolerability of FG-3019 administered over 8 weeks to adolescent and adult subjects with steroid-resistant focal segmental glomerulosclerosis (FSGS).
- Trial name
- NCT00782561
- Testing
- FG-3019
- Where
- 3 sites in United States
- Volunteers
- 2 people
- Sponsor
- Kyntra Bio
Kidney Diseases
China Kidney Patient Trials Network
This is a prospective multi-centre, observational cohort study of incident and prevalent patients diagnosed with a kidney disease in China.
- Trial name
- CKPTN (NCT05036850)
- Where
- China
- Volunteers
- 1,200 people
- Sponsor
- George (Beijing) Clinical Research Co. Ltd.
Kidney Transplantation, Primary Focal Segmental Glomerulosclerosis (FSGS)
Study to Assess the Efficacy and Safety of Bleselumab in Preventing the Recurrence of Focal Segmental Glomerulosclerosis in de Novo Kidney Transplant Recipients
The purpose of this study was to assess the efficacy of the bleselumab regimen (basiliximab induction, tacrolimus, steroids and bleselumab) compared with the Standard of Care (SOC) regimen (basiliximab induction, tacrolimus…
- Trial name
- NCT02921789
- Testing
- Bleselumab, Basiliximab, Mycophenolate Mofetil (MMF)
- Where
- 23 sites in United States, Canada
- Volunteers
- 67 people
- Sponsor
- Astellas Pharma Global Development, Inc.
Focal Segmental Glomerulosclerosis
A Study of Praliciguat in Participants With Focal Segmental Glomerulosclerosis (FSGS)
This is a Phase 2, randomized, double-blind, placebo-controlled, multicenter study designed to evaluate the efficacy and safety of praliciguat in adults with biopsy-confirmed focal segmental glomerulosclerosis (FSGS).
- Trial name
- NCT07268638
- Testing
- Praliciguat (Part A), Praliciguat (Part B)
- Where
- 30 sites in United States
- Volunteers
- 60 people
- Sponsor
- Akebia Therapeutics
Diabetic Kidney Disease, Diabetic Nephropathy
A Study in Participants With Diabetic Kidney Disease
The purpose of this study is to determine if LY2382770 is safe and effective at protecting kidney function in participants with kidney disease due to diabetes.
- Conditions
- Diabetic Kidney Disease, Diabetic Nephropathy, Diabetic Glomerulosclerosis
- Trial name
- NCT01113801
- Testing
- LY2382770
- Where
- 78 sites in United States, Australia and 5 more
- Volunteers
- 417 people
- Sponsor
- Eli Lilly and Company
Focal Segmental Glomerulosclerosis, Minimal Change Disease
Study of Sparsentan Treatment in Pediatrics With Proteinuric Glomerular Diseases
To evaluate the safety, efficacy and tolerability of sparsentan oral suspension and tablets, and assess changes in proteinuria after once-daily dosing over 108 weeks.
- Conditions
- Focal Segmental Glomerulosclerosis, Minimal Change Disease, Immunoglobulin A Nephropathy, IgA Vasculitis
- Trial name
- EPPIK (NCT05003986)
- Testing
- Sparsentan
- Where
- 47 sites in United States, Germany and 6 more
- Volunteers
- 67 people
- Sponsor
- Travere Therapeutics, Inc.
Idiopathic Focal Segmental Glomerulosclerosis
Acthar for Treatment-Resistant or Treatment-Intolerant Proteinuria
Focal segmental glomerulosclerosis (FSGS) is a condition that harms the kidney "filters" that remove waste from the blood. Proteins are supposed to stay in the blood. Damaged "filters" let protein get into the kidney.
- Trial name
- PODOCYTE (NCT02633046)
- Testing
- Acthar Gel
- Where
- 47 sites in United States, Argentina and 5 more
- Volunteers
- 63 people
- Sponsor
- Mallinckrodt ARD LLC
FSGS
A Study of the Efficacy and Safety of DMX-200 in Patients With FSGS Who Are Receiving an ARB
DMX-200 (repagermanium) is a C-C chemokine receptor type 2 (CCR2) inhibitor that, when administered concurrently with an ARB, is designed to inhibit recruitment of monocytes implicated in the inflammatory chemokine environment of…
- Trial name
- ACTION3 (NCT05183646)
- Testing
- DMX-200
- Where
- 220 sites in United States, Argentina and 19 more
- Volunteers
- 286 people
- Sponsor
- Dimerix Bioscience Pty Ltd
Focal Segmental Glomerulosclerosis
Dose-Exploration Evaluating the Efficacy and Safety of Voclosporin in Subjects With Focal Segmental Glomerulosclerosis
Evaluating the Efficacy and Safety of Voclosporin in Achieving Complete or Partial Remission of Proteinuria in Subjects with Focal Segmental Glomerulosclerosis
- Trial name
- AURONA™ (NCT03598036)
- Testing
- Voclosporin
- Where
- 23 sites in United States, Dominican Republic
- Volunteers
- 5 people
- Sponsor
- Aurinia Pharmaceuticals Inc.
Glomerulosclerosis, Focal Segmental, Minimal Change Disease
A Study to Understand the Genetics and Clinical Course of Focal Segmental Glomerulosclerosis (FSGS), Treatment-Resistant Minimal Change Disease (TR-MCD), and Diabetic Nephropathy (DN)
This is a study with 2 parts. Part 1 comprises a visit to collect biological samples necessary for the molecular characterization of chronic kidney disease.
- Conditions
- Glomerulosclerosis, Focal Segmental, Minimal Change Disease, Diabetic Nephropathies
- Trial name
- NCT04235621
- Testing
- FSGS/TR-MCD, Diabetic Nephropathy (DN)
- Where
- 18 sites in United States
- Volunteers
- 20 people
- Sponsor
- Goldfinch Bio, Inc.
Focal Segmental Glomerulosclerosis, Glomerulonephritis Minimal Lesion
A Study to Evaluate the Efficacy and Safety of Frexalimab, Brivekimig, or Rilzabrutinib in Participants Aged 16 to 75 Years With Primary Focal Segmental Glomerulosclerosis or Minimal Change Disease
This is a parallel, Phase 2a, double-blind, 6-arm study for the treatment of primary focal segmental glomerulosclerosis (FSGS) or minimal change disease (MCD).
- Trial name
- RESULT (NCT06500702)
- Testing
- frexalimab, brivekimig, rilzabrutinib
- Where
- 79 sites in United States, Argentina and 20 more
- Volunteers
- 84 people
- Sponsor
- Sanofi
Kidney Diseases, Diabetic Nephropathies
A Study of TRPC5 Channel Inhibitor in Patients With Diabetic Nephropathy, Focal Segmental Glomerulosclerosis, and Treatment-Resistant Minimal Change Disease
This is a phase 2a study evaluating the safety and tolerability of multiple ascending doses of GFB-887 in patients with diabetic nephropathy (DN), focal segmental glomerulosclerosis (FSGS), and treatment-resistant minimal change…
- Conditions
- Kidney Diseases, Diabetic Nephropathies, Glomerulosclerosis, Focal Segmental, Nephrosis, Lipoid
- Trial name
- NCT04387448
- Testing
- GFB-887
- Where
- 74 sites in United States
- Volunteers
- 96 people
- Sponsor
- Goldfinch Bio, Inc.
Primary Focal Segmental Glomerulosclerosis
A Study of Fresolimumab in Patients With Steroid-Resistant Primary Focal Segmental Glomerulosclerosis (FSGS)
The primary objectives of this trial are as follows: to compare the achievement of a partial remission (PR) or complete remission (CR) in urinary protein: creatinine ratio (Up/c ratio) in patients treated with fresolimumab versus…
- Trial name
- FSGS (NCT01665391)
- Testing
- fresolimumab
- Where
- 32 sites in United States, Brazil and 3 more
- Volunteers
- 36 people
- Sponsor
- Genzyme, a Sanofi Company
Focal Segmental Glomerulosclerosis
Post Approval Study of Liposorber LA-15 System for the Treatment of Focal Segmental Glomerulosclerosis in Children
Liposorber® LA-15 System is a blood purification therapy that selectively removes malignant lipoproteins including low density lipoprotein from circulating blood flow and rapidly reduces the plasma cholesterol level.
- Trial name
- FSGS pediatric (NCT02235857)
- Testing
- LIPOSORBER® LA-15 System
- Where
- 12 sites in United States
- Volunteers
- 35 people
- Sponsor
- Kaneka Medical America LLC
Focal Segmental Glomerulosclerosis (FSGS)
A Study to Evaluate PF-06730512 in Adults With Focal Segmental Glomerulosclerosis (FSGS)
The purpose of this Phase 2 adaptive study is to evaluate the efficacy, safety, tolerability and pharmacokinetics of PF-06730512 following multiple intravenous infusions in adult subjects with FSGS.
- Trial name
- PODO (NCT03448692)
- Testing
- PF-06730512
- Where
- 110 sites in United States, Canada and 10 more
- Volunteers
- 47 people
- Sponsor
- Pfizer
Focal Segmental Glomerulosclerosis
Safety and Effectiveness of Propagermanium in Focal Segmental Glomerulosclerosis Participants Receiving Irbesartan
This study will be evaluating the safety and efficacy of propagermanium for the treatment of participants with FSGS who are already taking irbesartan by: monitoring symptoms that participants may experience while on the study…
- Trial name
- ACTION (NCT03649152)
- Testing
- Propagermanium
- Where
- 11 sites in Australia
- Volunteers
- 8 people
- Sponsor
- Dimerix Bioscience Pty Ltd
Glomerulosclerosis, Focal Segmental
Phase 2a Study of VX-147 in Adults With APOL1-mediated Focal Segmental Glomerulosclerosis
This study will evaluate the efficacy, safety and pharmacokinetics (PK) of VX-147 in participants with apolipoprotein L1 (APOL1)-mediated focal segmental glomerulosclerosis (FSGS).
- Trial name
- NCT04340362
- Testing
- VX-147
- Where
- 44 sites in United States, France and 2 more
- Volunteers
- 16 people
- Sponsor
- Vertex Pharmaceuticals Incorporated
Nephrotic Syndrome
Part 1 - A Clinical Trial in Patients With Frequently Relapsing and Steroid-Dependent Nephrotic Syndrome
A Clinical Trial Investigating the Safety and Efficacy of ADX-629 in Subjects with Frequently Relapsing and Steroid-Dependent Nephrotic Syndrome
- Trial name
- NCT05599815
- Testing
- ADX-629
- Where
- 11 sites in United States
- Sponsor
- Aldeyra Therapeutics, Inc.
Minimal Change Disease (MCD), IgA Nephropathy (IgAN)
Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of EVER001 in Participants With Selected Proteinuric Glomerular Diseases
This is a Phase 1b/2, open-label, multi-center study evaluating the therapeutic potential and safety of the investigational drug EVER001 in adults with FSGS, MCD, or IgAN.
- Conditions
- Minimal Change Disease (MCD), IgA Nephropathy (IgAN), Focal Segmental Glomerulosclerosis (FSGS)
- Trial name
- NCT07614477
- Testing
- EVER001
- Where
- 2 sites in China
- Volunteers
- 45 people
- Sponsor
- Everest Medicines (China) Co.,Ltd.
Focal Segmental Glomerulosclerosis
Safety Study of GC1008 in Patients With Focal Segmental Glomerulosclerosis (FSGS) of Single Doses of GC1008 in Patients With Treatment Resistant Idiopathic FSGS
This study will investigate whether GC1008, an antibody which neutralizes TGF-beta, is safe in treating patients with the disease called focal segmental glomerulosclerosis (FSGS).
- Trial name
- NCT00464321
- Testing
- GC1008
- Where
- 9 sites in United States, Germany and 2 more
- Volunteers
- 16 people
- Sponsor
- Genzyme, a Sanofi Company